Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMG2MSX)

Drug Name
N-(2-aminoethyl)isoquinoline-5-sulfonamide Drug Info
Synonyms
N-(2-aminoethyl)isoquinoline-5-sulfonamide; AEIQS; 84468-17-7; N-(2-aminoethyl)-5-isoquinolinesulfonamide; Protein kinase C inhibitor H-9; H-9; (2-Aminoethyl)(5-isoquinolylsulfonyl)amine; 5-Isoquinolinesulfonamide, N-(2-aminoethyl)-; CHEMBL344314; DCVZSHVZGVWQKV-UHFFFAOYSA-N; H9; Isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide; C11H13N3O2S; BRD7657; BRD-7657; N-(2-aminoethyl]-5-isoquinolinesulfonamide; IQU; N-(2-Aminoethyl)isoquinoline-5-sulfonamide hydrochloride (H9); Tocris-0396; Lopac-H-123; AC1Q6ULL; H-9, DiHCl; AC1L1G6B
Cross-matching ID
PubChem CID
3544
ChEBI ID
CHEMBL344314
CAS Number
CAS 84468-17-7
TTD Drug ID
D0C8BV

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.10 0.00e+0 101/150 (67.33%) HSPA8;SF3B4;PRPF4;...
Allograft rejection 2.06 0.00e+0 32/38 (84.21%) HLA-DPA1;HLA-DRB1;HLA-DQB1;...
Antigen processing and presentation 1.99 0.00e+0 60/78 (76.92%) HSPA8;HLA-DPA1;HLA-DRB1;...
Type I diabetes mellitus 1.85 1.51e-2 38/43 (88.37%) HSPD1;HLA-DPA1;HLA-DRB1;...
Autoimmune thyroid disease 1.83 1.69e-2 46/53 (86.79%) HLA-DPA1;HLA-DRB1;HLA-DQB1;...
Proteasome 1.82 1.61e-2 44/46 (95.65%) PSME3;PSMD12;PSME2;...
Graft-versus-host disease 1.81 1.56e-2 32/42 (76.19%) HLA-DPA1;HLA-DRB1;HLA-DQB1;...
Leishmaniasis 1.78 2.57e-2 67/77 (87.01%) HLA-DPA1;PTGS2;HLA-DRB1;...
Citrate cycle (TCA cycle) 1.77 2.56e-2 30/30 (100%) PCK1;DLD;SDHD;...
Viral myocarditis 1.76 2.54e-2 53/60 (88.33%) HLA-DPA1;HLA-DRB1;HLA-DQB1;...
Diabetic cardiomyopathy 1.76 2.42e-2 162/203 (79.8%) MMP9;PIK3R1;NDUFAB1;...
Prion disease 1.73 3.23e-2 209/273 (76.56%) HSPA8;CCL5;PIK3R1;...
Huntington disease 1.72 3.35e-2 233/306 (76.14%) NDUFAB1;PLCB3;ATP5MC3;...
Cell adhesion molecules 1.70 3.63e-2 118/148 (79.73%) CDH1;HLA-DPA1;CD2;...
Systemic lupus erythematosus 1.69 3.95e-2 45/135 (33.33%) C7;HLA-DPA1;HLA-DRB1;...
Oxidative phosphorylation 1.68 4.24e-2 93/133 (69.92%) NDUFAB1;ATP5MC3;ATP6V1D;...
Inflammatory bowel disease 1.67 4.70e-2 58/65 (89.23%) HLA-DPA1;HLA-DRB1;TGFB1;...
RNA polymerase 1.67 4.51e-2 23/31 (74.19%) POLR2B;POLR2D;POLR1B;...
Primary immunodeficiency 1.67 4.27e-2 33/38 (86.84%) IL7R;CD19;TAP1;...
Asthma 1.67 4.36e-2 25/31 (80.65%) HLA-DPA1;HLA-DRB1;HLA-DQB1;...
Rheumatoid arthritis 1.65 4.61e-2 78/93 (83.87%) CCL5;CCL2;HLA-DPA1;...
Th1 and Th2 cell differentiation 1.65 4.40e-2 80/92 (86.96%) HLA-DPA1;HLA-DRB1;HLA-DQB1;...
Parkinson disease 1.62 4.89e-2 176/249 (70.68%) NDUFAB1;ATP5MC3;CYCS;...
Mineral absorption -1.81 1.36e-2 48/60 (80%) TF;MT1F;ATP7A;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.90 1.30e-2 20/26 (76.92%) PIGN;PIGP;PIGF;...
Galactose metabolism -1.92 7.79e-3 26/31 (83.87%) UGP2;GALK1;GALT;...
Amino sugar and nucleotide sugar metabolism -2.17 0.00e+0 38/48 (79.17%) UAP1;UGP2;GALK1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HAP1 CVCL_Y019 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 BRD4 (-) 1 CVCL_SF59 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 CDK4 (-) 1 CVCL_SI36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 HDAC5 (-) 1 CVCL_SR11 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 ITGA4 (-) 1 CVCL_ST27 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 MAPK8 (-) 1 CVCL_SW99 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PIK3CA (-) 1 CVCL_TD60 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKACA (-) 1 CVCL_TG70 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 PRKCQ (-) CVCL_TG92 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 RELA (-) 1 CVCL_TI75 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 SRC (-) 1 CVCL_TQ36 Homo sapiens 0.66uM - 3.33uM 24H
HAP1 TP53 (-) 1 CVCL_RJ70 Homo sapiens 0.66uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.66uM - 10uM 6H, 24H